Clinical Trial: Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age
Study Status: Completed
Recruit Status: RECRUITING
Condition: Allergy, Peanut
Study Type: INTERVENTIONAL
Official Title: A Phase 3, Double-blind, Placebo-controlled, Randomized Study to Assess the Efficacy and Safety of Epicutaneous Immunotherapy With DBV712 250 ?g in 4-7-year-old Children With Peanut Allergy (VITESSE)
Brief Summary:
The primary purpose of this study is to assess the efficacy and safety of daily DBV712 250 micrograms (mcg) to induce desensitization to peanut in peanut-allergic children 4-7 years of age over a 12-month treatment period.
Read more